Quick Answer
Apyx Medical Corp reported Cash and Equivalents of $31.74 million for fiscal year 2025.
Apyx Medical Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $31.74M | -0.0% |
| 2024 | $31.74M | -27.3% |
| 2023 | $43.65M | +328.3% |
| 2022 | $10.19M | -67.0% |
| 2021 | $30.87M | -26.4% |
| 2020 | $41.91M | -28.7% |
| 2019 | $58.81M | +81.4% |
| 2019 | $32.41M | +95.3% |
| 2018 | $16.60M | -59.2% |
| 2018 | $40.66M | +308.7% |
| 2017 | $9.95M | -31.2% |
| 2016 | $14.46M | +22.5% |
| 2015 | $11.80M | +105.9% |
| 2014 | $5.73M | -27.7% |
| 2013 | $7.92M | +90.4% |
| 2012 | $4.16M | -14.7% |
| 2011 | $4.88M | +27.5% |
| 2010 | $3.83M | +77.6% |
| 2009 | $2.15M | -16.0% |
| 2008 | $2.56M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.14M | -10.3% | -14.2% |
| June 30, 2025 | $29.30M | -10.3% | -5.5% |
| March 31, 2025 | $31.01M | -16.8% | -2.3% |
| December 31, 2024 | $31.74M | -27.3% | +13.3% |
| September 30, 2024 | $28.01M | +26.6% | -14.3% |
| June 30, 2024 | $32.68M | +76.8% | -12.3% |
| March 31, 2024 | $37.28M | +129.4% | -14.6% |
| December 31, 2023 | $43.65M | +328.3% | +97.2% |
- Apyx Medical Corp showed a decrease of -0.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Apyx Medical Corp’s cash and equivalents has grown by 1137.9% (from $2.56 million to $31.74 million).
- The most recent figure is from Apyx Medical Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: